Advertisement

Immunohistochemistry for Protein Detection in Esophageal Squamous Cell Carcinoma

  • Kais KasemEmail author
  • Alfred K. LamEmail author
Protocol
  • 58 Downloads
Part of the Methods in Molecular Biology book series (MIMB, volume 2129)

Abstract

Immunohistochemistry is the identification of a cell protein by a specific antibody targeting that protein. It is the most common ancillary test to study the pathology of cancer. Immunohistochemical protein markers are used to differentiate poorly differentiated squamous cell carcinoma from poorly differentiated adenocarcinoma or neuroendocrine carcinomas. They could be used to identify and type the carcinoma in metastatic locations. Importantly, immunodetection of markers also helps in prediction of response to therapies as well as assessing the different biomarkers related to the pathogenesis and clinical behavior of esophageal squamous cell carcinoma. Successful application of the immunochemistry depends on understanding the mechanisms and principles as well as the limitations of the procedure. Automation of the procedure by different models of automatic stainers is widely used in diagnostic laboratories. The use of autostainers streamlines the workflows and certainly reduces the labor, time, and cost of using immunohistochemistry in clinical and research settings.

Key words

Immunohistochemical Immunohistochemistry Esophagus Squamous cell carcinoma Autostainer 

References

  1. 1.
    Lam KY, Ma LT, Wong J (1996) Measurement of extent of spread of oesophageal squamous carcinoma by serial sectioning. J Clin Pathol 49:124–129CrossRefGoogle Scholar
  2. 2.
    Lam AK, Kumarasinghe MP (2019) Adenocarcinoma of the oesophagus and oesophagogastric junction NOS. In: Odze RD, Lam AK, Ochiai A, Washington MK (eds) WHO classification of tumours, 5th edn, pp 38–43, Chapter 2Google Scholar
  3. 3.
    Lam KY, Law S, Tung PH, Wong J (2000) Esophageal small cell carcinomas: clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis. Arch Pathol Lab Med 124:228–233PubMedGoogle Scholar
  4. 4.
    Ng HY, Li J, Tao L, Lam AK, Chan KW, Ko JM, Yu VZ, Wong M, Li B, Lung ML (2018) Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR/ERK activation. Transl Oncol 11:1323–1333CrossRefGoogle Scholar
  5. 5.
    Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856CrossRefGoogle Scholar
  6. 6.
    Nebot-Bral L, Coutzac C, Kannouche PL, Chaput N (2019) Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Bull Cancer 106:105–113CrossRefGoogle Scholar
  7. 7.
    Islam F, Gopalan V, Law S, Tang JC, Lam AK (2019) FAM134B promotes esophageal squamous cell carcinoma in vitro and its correlations with clinicopathologic features. Hum Pathol 87:1–10CrossRefGoogle Scholar
  8. 8.
    Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, Lee AW, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML (2016) Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget 7:78859–78871CrossRefGoogle Scholar
  9. 9.
    Yu VZ, Wong VC, Dai W, Ko JM, Lam AK, Chan KW, Samant RS, Lung HL, Shuen WH, Law S, Chan YP, Lee NP, Tong DK, Law TT, Lee VH, Lung ML (2015) Nuclear localization of DNAJB6 is associated with survival of patients with esophageal cancer and reduces AKT signaling and proliferation of cancer cells. Gastroenterology 149:1825–1836CrossRefGoogle Scholar
  10. 10.
    Chan D, Tsoi MY, Liu CD, Chan SH, Law SY, Chan KW, Chan YP, Gopalan V, Lam AK, Tang JC (2013) Oncogene GAEC1 regulates CAPN10 expression which predicts survival in esophageal squamous cell carcinoma. World J Gastroenterol 19:2772–2780CrossRefGoogle Scholar
  11. 11.
    Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G (2006) Clinical relevance of Fas expression in oesophageal squamous cell carcinoma. J Clin Pathol 59:101–104CrossRefGoogle Scholar
  12. 12.
    Lam KY, Law S, Tin L, Tung PH, Wong J (1999) The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol 94:2060–2068CrossRefGoogle Scholar
  13. 13.
    Lam KY, L oke SL, Chen WZ, Cheung KN, Ma L (1995) Expression of p53 in oesophageal squamous cell carcinoma in Hong Kong Chinese. Eur J Surg Oncol 21:242–247CrossRefGoogle Scholar
  14. 14.
    Lam KY, Law S, Ma LT, Ong SK, Wong J (1997) Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: do histological assessment and p53 overexpression predict chemo-responsiveness? Eur J Cancer 33:1221–1225CrossRefGoogle Scholar
  15. 15.
    Law AK, Lam KY, Lam FK, Wong TK, Poon JL, Chan FH (2003) Image analysis system for assessment of immunohistochemically stained proliferative marker (MIB-1) in oesophageal squamous cell carcinoma. Comput Methods Prog Biomed 70:37–45CrossRefGoogle Scholar
  16. 16.
    Lam KY, Law SY, So MK, Fok M, Ma LT, Wong J (1996) Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer 77:7–13CrossRefGoogle Scholar
  17. 17.
    Xu WW, Li B, Lam AK, Tsao SW, Law SY, Chan KW, Yuan QJ, Cheung AL (2015) Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget 6:1790–1805PubMedPubMedCentralGoogle Scholar
  18. 18.
    Ramos-Vara JA (2011) Principles and methods of immunohistochemistry. In: Drug safety evaluation. Humana Press, Totowa, New Jersey, pp 83–96CrossRefGoogle Scholar
  19. 19.
    Kabiraj A, Gupta J, Khaitan T, Bhattacharya PT (2015) Principle and techniques of immunohistochemistry—a review. Int J Biol Med Res 6:5204–5210Google Scholar
  20. 20.
    Renshaw S (2006) Immunohistochemistry: methods express. Royal College of general practitioners. Scion Publishing, BanburyGoogle Scholar
  21. 21.
  22. 22.
    Hewitt SM, Baskin DG, Frevert CW, Stahl WL, Rosa-Molinar E (2014) Controls for immunohistochemistry: the Histochemical Society’s standards of practice for validation of immunohistochemical assays. J Histochem Cytochem 62:693–697CrossRefGoogle Scholar
  23. 23.
    Scalia CR, Boi G, Bolognesi MM, Riva L, Manzoni M, DeSmedt L, Bosisio FM, Ronchi S, Leone BE, Cattoretti G (2017) Antigen masking during fixation and embedding, dissected. J Histochem Cytochem 65:5–20CrossRefGoogle Scholar
  24. 24.
  25. 25.
    Webster JD, Miller MA, DuSold D, Ramos-Vara J (2009) Effects of prolonged formalin fixation on diagnostic immunohistochemistry in domestic animals. J Histochem Cytochem 57:753–761CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Clinical Pathology Department, Melbourne Medical SchoolUniversity of MelbourneMelbourneAustralia
  2. 2.Cancer Molecular Pathology, School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations